News

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).

Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.

All in the Family: The many branches of the CMTA family tree—the patients, the families that support them and the doctors who treat them.

Swim in a cool lake. Make a new friend. Practice archery or ride a horse. Remember what summer camp was like; then see what it was like at Camp Footprint, the only camp in the U.S. solely for kids ...

In her own words, Riley wants you to know why Camp Footprint has become her “most favorite week out of the entire year.”